Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EXELON

« Back to Dashboard

Exelon is a drug marketed by Novartis and is included in three NDAs. It is available from four suppliers. There are three patents protecting this drug and four Paragraph IV challenges.

The generic ingredient in EXELON is rivastigmine tartrate. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the rivastigmine tartrate profile page.

Summary for Tradename: EXELON

Suppliers: see list4

Pharmacology for Tradename: EXELON

Clinical Trials for: EXELON

Rivastigmine as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Status: Recruiting Condition: Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers
Status: Completed Condition: Rivastigmine Toxicity

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Status: Completed Condition: Parkinson's Disease Dementia

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Status: Completed Condition: Alzheimer's Disease

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
Status: Recruiting Condition: Alzheimer's Dementia

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Status: Completed Condition: Alzheimer Disease

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Status: Completed Condition: Alzheimer Disease

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
Status: Completed Condition: Delirium; Postoperative Cognitive Dysfunction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXYes<disabled><disabled>
rivastigmine tartrate
CAPSULE; ORAL020823Apr 21, 2000RXNo4,948,807<disabled>Y<disabled>
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXNo<disabled><disabled>
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXYes5,602,176<disabled>YY<disabled>
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXNo6,335,031<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EXELON

Drugname Dosage Strength RLD Submissiondate
rivastigmineTransdermal System Extended-release13.3 mg/24 hrExelon1/22/2013
rivastigmineTransdermal System Extended-release4.6 mg/24 hr and 9.5 mg/24 hrExelon Patch4/27/2011
rivastigmine tartrateOral Solution2 mg/mLExelon11/5/2004
rivastigmine tartrateCapsules1.5 mg, 3 mg, 4.5 mg and 6 mgExelon4/21/2004
« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology